Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Non-Current Assets of $45.5 million for Q2 2026, up 278.09% year-over-year from $12.0 million in Q2 2025, and up 0.99% quarter-over-quarter from $45.0 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Non-Current Assets for 17 consecutive years, with $45.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets rose 278.09% year-over-year to $45.5 million; the TTM figure through Jun 2026 stood at $120.1 million (up 203.28% YoY), while the FY2025 annual figure was $13.8 million, up 48.27% from the prior year.
- Non-Current Assets rose to $45.5 million in Q2 2026 per MDGL's latest filing, from $45.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $45.5 million in Q2 2026 and bottomed at $866000.0 in Q2 2023.
- Historically, Non-Current Assets has averaged $10.6 million across 5 years, with a median of $8.2 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 53.09% — and 2024, when it soared 830.83%.
- Madrigal Pharmaceuticals' Non-Current Assets stood at $1.2 million in 2022, then surged by 171.49% to $3.3 million in 2023, then soared by 185.36% to $9.3 million in 2024, then soared by 48.27% to $13.8 million in 2025, then surged by 229.0% to $45.5 million in 2026.
- Business Quant data shows MDGL's Non-Current Assets at $45.5 million in Q2 2026, $45.0 million in Q1 2026, and $13.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 45.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.47 Mn |
| Mar 31, 2026 | 45.02 Mn |
| Dec 31, 2025 | 13.82 Mn |
| Sep 30, 2025 | 15.78 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Mar 31, 2025 | 8.65 Mn |
| Dec 31, 2024 | 9.32 Mn |
| Sep 30, 2024 | 9.60 Mn |
| Jun 30, 2024 | 8.06 Mn |
| Mar 31, 2024 | 8.33 Mn |
| Dec 31, 2023 | 3.27 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Jun 30, 2023 | 866,000.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.85 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.74 Mn |